Citius Oncology, Inc. CTOR R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s r&d credit carryforward?
- Citius Oncology, Inc. (CTOR) reported r&d credit carryforward of $1.58M in Q3 2025.
- What is the long-term trend for Citius Oncology, Inc.'s r&d credit carryforward?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s r&d credit carryforward has grown at a 36.4% compound annual growth rate (CAGR), from $850K to $1.58M.
- What does r&d credit carryforward mean?
- This represents the value of research and development tax credits that the company has earned but has not yet been able to utilize to offset tax liabilities. These carryforwards can be used to reduce future tax payments, providing a potential liquidity benefit. It reflects the company's historical investment in innovation and its ability to manage future tax burdens.